{"prompt": "['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '14', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', '4.2.1.5', 'Planned Exploratory Biomarker Research', '54', '4.2.2', 'Rationale for the Use of Comparator/Placebo', '56', '4.3', 'Justification for Dose', '56', '4.3.1', 'Maximum Dose/Exposure for This Study', '56', '4.3.2', 'Rationale for Dose Interval and Study Design', '56', '4.3.2.1', 'Lenvatinib Dosing', '56', '4.3.2.2', 'Pembrolizumab Dosing', '57', '4.4', 'Beginning and End of Study Definition', '58', '4.4.1', 'Clinical Criteria for Early Study Termination', '58', '5', 'STUDY POPULATION', '58', '5.1', 'Inclusion Criteria', '58', '5.2', 'Exclusion Criteria', '63', '5.3', 'Lifestyle Considerations', '66', '5.3.1', 'Meals and Dietary Restrictions', '66', '5.3.2', 'Contraception', '66', '5.3.3', 'Pregnancy', '66', '5.3.4', 'Use in Nursing Women', '67', '5.4', 'Screen Failures', '67', '5.5', 'Participant Replacement Strategy', '67', '6', 'STUDY INTERVENTION', '67', '6.1', 'Study Intervention(s) Administered', '67', '6.1.1', 'Medical Devices', '69', '6.2', 'Preparation/Handling/Storage/Accountability', '69', '6.2.1', 'Dose Preparation', '69', '6.2.2', 'Handling, Storage, and Accountability', '69', '6.3', 'Measures to Minimize Bias: Randomization and Blinding', '70', '6.3.1', 'Intervention Assignment', '70', '6.3.2', 'Stratification', '70', '6.3.3', 'Blinding', '70', '6.3.3.1', 'Pembrolizumab', '70', '6.4', 'Study Intervention Compliance', '71', '6.5', 'Concomitant Therapy', '71', '6.5.1', 'Allowed Concomitant Medications', '71', '6.5.2', 'Prohibited Concomitant Medications', '72', '6.5.3', 'Drug Interactions', '72', '6.5.4', 'Rescue Medications and Supportive Care', '73', '6.5.4.1', 'Systemic Corticosteroid Use', '73', '6.6', 'Dose Modification', '73', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '15', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', '6.6.1', 'Immune-related Events and Dose Modification (Withhold, Treat,', 'Discontinue)', '73', '6.6.1.1', 'Dose Modification and Toxicity Management for Immune-related', 'AEs Associated with Pembrolizumab', '73', '6.6.1.2', 'Dose Modification and Toxicity Management of Infusion', 'Reactions Related to Pembrolizumab', '79', '6.6.2', 'Other Allowed Dose Interruptions', '82', '6.7', 'Intervention After the End of the Study', '82', '6.8', 'Clinical Supplies Disclosure', '82', '6.9', 'Standard Policies', '82', '7', 'DISCONTINUATION OF STUDY INTERVENTION AND PARTICIPANT', 'WITHDRAWAL', '82', '7.1', 'Discontinuation of Study Intervention', '82', '7.1.1', 'Second-course Treatment Phase', '83', '7.2', 'Participant Withdrawal From the Study', '83', '7.3', 'Lost to Follow-up', '84', '8', 'STUDY ASSESSMENTS AND PROCEDURES', '84', '8.1', 'Administrative and General Procedures', '85', '8.1.1', 'Informed Consent', '85', '8.1.1.1', 'General Informed Consent', '85', '8.1.2', 'Inclusion/Exclusion Criteria', '86', '8.1.3', 'Participant Identification Card', '86', '8.1.4', 'Medical History', '86', '8.1.4.1', 'General Medical History', '86', '8.1.4.2', 'Oncologic Disease Details', '86', '8.1.5', 'Prior and Concomitant Medications Review', '87', '8.1.5.1', 'Prior Medications', '87', '8.1.5.2', 'Prior Oncologic Treatment', '87', '8.1.5.3', 'Concomitant Medications', '87', '8.1.6', 'Assignment of Screening Number', '87', '8.1.7', 'Assignment of Treatment/Randomization Number', '88', '8.1.8', 'Study Intervention Administration', '88', '8.1.8.1', 'Timing of Dose Administration', '88', '8.1.8.1.1', 'Lenvatinib/Matching Placebo', '88', '8.1.8.1.2', 'Pembrolizumab', '88', '8.1.8.2', 'Lenvatinib Compliance', '89', '8.1.9', 'Discontinuation and Withdrawal', '89', '8.1.10', 'Participant Blinding/Unblinding', '89', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']\n\n###\n\n", "completion": "END"}